Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

A University of Colorado Cancer Center study shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" to show benefit from anti-androgen therapies. There are no FDA-approved targeted therapies for triple-negative breast cancer. Clinical trials currently underway are showing promising preliminary results of anti-androgen-receptor therapies against triple-negative breast cancers expressing a higher percentage of androgen-receptor-positive cells. Read more here.